MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. The company is headquartered in Chicago, Illinois and currently employs 13 full-time employees. The company went IPO on 2022-07-28. The firm's THIO (6-thio-dG, 6-thio-2'-deoxyguanosine), is a lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The modified nucleotide 6-thio-2-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in tumor regression in advanced, in vivo cancer models by induction of cancer type-specific immune memory. THIO is being developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
Follow-Up Questions
Who is the CEO of Maia Biotechnology Inc?
Dr. Vlad Vitoc is the Chairman of the Board of Maia Biotechnology Inc, joining the firm since 2018.
What is the price performance of MAIA stock?
The current price of MAIA is $1.2, it has increased 3.92% in the last trading day.
What are the primary business themes or industries for Maia Biotechnology Inc?
Maia Biotechnology Inc belongs to Biotechnology industry and the sector is Health Care
What is Maia Biotechnology Inc market cap?
Maia Biotechnology Inc's current market cap is $39.7M
Is Maia Biotechnology Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Maia Biotechnology Inc, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
